94,400 Shares in DENTSPLY SIRONA Inc. $XRAY Bought by Skylands Capital LLC

Key Points

• Skylands Capital bought a new stake of 94,400 shares of DENTSPLY SIRONA (XRAY) in Q4 (≈$1.08M), while other institutions—most notably UBS, which added 662,000 shares to hold 1.701M—help push institutional ownership to about 95.7%.
• Insiders purchased a total of 70,000 shares (~$956k) over the last quarter, including Director James D. Forbes (5,000 shares at $12.48) and Director Gregory T. Lucier (27,555 shares at $14.24), but insiders still only own about 0.5% of the stock.
• Analysts show a mixed view with an average rating of Hold and a $14.08 target; XRAY trades around $11.96 with a negative P/E (~-3.99) and company FY2026 guidance of 1.40–1.50 EPS.

Skylands Capital LLC bought a new stake in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 94,400 shares of the medical instruments supplier's stock, valued at approximately $1,079,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Mitsubishi UFJ Trust & Banking Corp grew its position in shares of DENTSPLY SIRONA by 35.9% during the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 143,977 shares of the medical instruments supplier's stock valued at $1,646,000 after purchasing an additional 38,039 shares in the last quarter. UBS Group AG lifted its position in shares of DENTSPLY SIRONA by 63.7% in the fourth quarter. UBS Group AG now owns 1,701,980 shares of the medical instruments supplier's stock worth $19,454,000 after buying an additional 662,000 shares in the last quarter. Sanctuary Advisors LLC boosted its stake in DENTSPLY SIRONA by 9.8% during the fourth quarter. Sanctuary Advisors LLC now owns 29,226 shares of the medical instruments supplier's stock valued at $334,000 after buying an additional 2,599 shares during the last quarter. Marathon Capital Management grew its holdings in DENTSPLY SIRONA by 80.0% during the 4th quarter. Marathon Capital Management now owns 46,040 shares of the medical instruments supplier's stock valued at $526,000 after buying an additional 20,465 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in DENTSPLY SIRONA by 43.5% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 48,280 shares of the medical instruments supplier's stock valued at $552,000 after buying an additional 14,645 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors.

Insider Activity

In other DENTSPLY SIRONA news, Director James D. Forbes purchased 5,000 shares of DENTSPLY SIRONA stock in a transaction dated Monday, March 9th. The shares were purchased at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the completion of the acquisition, the director owned 10,000 shares in the company, valued at $124,800. This represents a 100.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gregory T. Lucier purchased 27,555 shares of the firm's stock in a transaction that occurred on Monday, March 2nd. The shares were acquired at an average cost of $14.24 per share, with a total value of $392,383.20. Following the completion of the purchase, the director directly owned 27,555 shares in the company, valued at $392,383.20. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 70,000 shares of company stock worth $956,437 over the last quarter. 0.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

XRAY has been the topic of several recent research reports. Zacks Research raised DENTSPLY SIRONA from a "strong sell" rating to a "hold" rating in a report on Monday, March 2nd. Citigroup began coverage on shares of DENTSPLY SIRONA in a research report on Wednesday, April 15th. They issued a "sell" rating and a $10.00 price target on the stock. Bank of America raised shares of DENTSPLY SIRONA from a "neutral" rating to a "buy" rating and upped their price target for the company from $13.00 to $17.00 in a research note on Thursday, February 19th. Mizuho increased their price objective on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the company a "neutral" rating in a research report on Monday, March 2nd. Finally, Wells Fargo & Company lifted their price objective on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an "equal weight" rating in a research note on Friday, February 27th. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, DENTSPLY SIRONA has an average rating of "Hold" and an average target price of $14.08.

DENTSPLY SIRONA Price Performance

NASDAQ:XRAY opened at $11.96 on Tuesday. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of -3.99, a PEG ratio of 1.40 and a beta of 0.99. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. The business has a 50 day simple moving average of $12.21 and a 200-day simple moving average of $12.04. DENTSPLY SIRONA Inc. has a 1 year low of $9.85 and a 1 year high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). The company had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.43 EPS for the current year.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.